

Serial No.: 09/302,024  
Group Art Unit: 1652



**In the Claims:**

Please cancel claims 13, 14, and 16-19 without prejudice or disclaimer of the subject matter contained therein and enter the following new claims:

-- 28. An isolated polypeptide comprising an amino acid sequence having at least 95% identity with the amino acid sequence set forth in SEQ ID NO:2 and wherein the isolated polypeptide is effective to induce antibodies to a polypeptide having the sequence of SEQ ID NO:2.

-- 29. The isolated polypeptide of claim 28, wherein the amino acid sequence has at least 97% identity with the amino acid sequence set forth in SEQ ID NO:2 and wherein the isolated polypeptide is effective to induce antibodies to a polypeptide having the sequence SEQ ID NO:2.

-- 30. An isolated polypeptide comprising a polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO:2.

B' -- 31. A composition comprising the isolated polypeptide of claim 30 and a pharmaceutically acceptable carrier.

-- 32. The isolated polypeptide of claim 30, wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the polypeptide sequence.

-- 33. A composition comprising the isolated polypeptide of claim 32 and a pharmaceutically acceptable carrier.

-- 34. The isolated polypeptide of claim 30, wherein the isolated polypeptide consists of the polypeptide sequence.

RECEIVED  
MAR 23 2000  
TC 1600 MAIL ROOM

RECEIVED  
MAR 24 2000  
TC 1600 MAIL ROOM

- 35. A composition comprising the isolated polypeptide of claim 34 and a pharmaceutically acceptable carrier.
- 36. An isolated polypeptide comprising a polypeptide sequence comprising at least 50 consecutive amino acids of SEQ ID NO:2 and wherein the isolated polypeptide is effective to induce antibodies to a polypeptide having the sequence of SEQ ID NO:2.
- 37. A composition comprising the isolated polypeptide of claim 36 and a pharmaceutically acceptable carrier.
- 38. The isolated polypeptide of claim 36, wherein the isolated polypeptide comprises a heterologous amino acid sequence fused to the polypeptide sequence.
- 39. A composition comprising the isolated polypeptide of claim 38 and a pharmaceutically acceptable carrier.
- 40. The isolated polypeptide of claim 36, wherein the isolated polypeptide consists of the polypeptide sequence.
- 41. A composition comprising the isolated polypeptide of claim 40 and a pharmaceutically acceptable carrier.
- 42. An isolated polypeptide comprising a polypeptide sequence comprising at least 30 consecutive amino acids of SEQ ID NO:2 and wherein the isolated polypeptide is effective to induce antibodies to a polypeptide having the sequence of SEQ ID NO:2.
- 43. A composition comprising the isolated polypeptide of claim 42 and a pharmaceutically acceptable carrier.